



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.) INDIA.

Tel. : (0731) 2517677 E-mail : beryldrugs25@yahoo.com CIN : L02423MP1993PLC007840

Date: 30th May, 2018

To,

The Secretary,
Department of Corporate Services,
Bombay Stock Exchange Limited (BSE),
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai – 400001

Sub.: Disclosure of Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sirs,

Pursuant to Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors in its Board Meeting held on 30.05.2018 has approved the Audited Financial Results of the Company for the Quarter/ Financial Year ended 31st March, 2018. In this regard please find enclosed herewith the following:

- Audited Financial Results for the Quarter/ Financial year ended 31st March, 2018.
- Auditors Report on the Audited Financial Results for the Financial year ended 31st March, 2018
- Declaration pursuant to the Regulation 33(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We hereby request you to kindly acknowledge the receipts of same.

Thanking You,

Yours Sincerely

For Beryl Drugs Limited


Sudhir Sethi
Chairman & Director
DIN: 00090172





BERYL DRUGS LIMITED
 Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
 Tel./ Fax 0731-3961510
 E-mail : beryldrugs25@yahoo.com
 CIN : L02423MP1993PLC007840

ANNEXURE I

Submission of Unaudited/ Audited Financial Result by Companies Other than Banks

Part I (Rs in 000)

Statement of standalone / Consolidated / Audited Result for the Quarter/ year ended 31/03/2018

Particulars	3 months ended (31-03-2018)	Preceding 3 months ended (31-12-2017)	Corresponding 3 months ended in the previous year (31-03-2017)	Year to date figures for current period ended (31-03-2018)	Year to date figures for previous period ended (31-03-2017)	Previous year ended (31-03-2017)
	Audited	Unaudited	Unaudited	Audited	Audited	Audited
(Refer Notes Below)						
1 Revenue From Operations						
Net sales or Revenue from Operations	42552.000	36309.000	23783.000	152487.000	112677.000	112677.000
Other operating revenues	4775.000	36.000	1341.000	7382.000	2607.000	2607.000
Total Revenue from operations (net)	47327.000	36345.000	25124.000	159869.000	115284.000	115284.000
2 Expenses						
(a) Cost of materials consumed	20041.000	25732.000	-2583.000	89061.000	69426.000	69426.000
(b) Purchases of stock-in-trade	0.000	0.000	0.000	0.000	0.000	0.000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	8923.000	-119.000	1467.000	4464.000	-4459.000	-4459.000
(d) Employee benefit expense	-2520.000	2084.000	1819.000	7310.000	9787.000	9787.000
(e) Finance costs	-756.000	212.000	469.000	1323.000	2009.000	2009.000
(f) Depreciation and amortisation expense	-473.000	1000.000	770.000	3297.000	3776.000	3776.000
(g) Other Expenses	11608.000	6112.000	23177.000	42137.000	38350.000	38350.000
Total expenses	36823.000	35021.000	25119.000	147592.000	118889.000	118889.000
3 Profit (loss) from operations before exceptional and extraordinary items and tax	10504.000	1324.000	5.000	12277.000	-3605.000	-3605.000
4 Exceptional items	0.000	0.000	0.000	0.000	0.000	0.000
5 profit (loss) before extraordinary items and tax	10504.000	1324.000	5.000	12277.000	-3605.000	-3605.000
6 Extraordinary items	0.000	0.000	0.000	0.000	0.000	0.000
7 Profit (loss) before tax	10504.000	1324.000	5.000	12277.000	-3605.000	-3605.000
8 Tax Expense						
Current tax	1997.000	300.000	516.000	2604.000	873.000	873.000
Deferred tax	-256.000	0.000	-309.000	-256.000	-338.000	-338.000
Total Tax Expenses	1741.000	300.000	207.000	2348.000	535.000	535.000
9 Net Profit (loss) for the period from continuing operations	8763.000	1024.000	-202.000	9929.000	-4140.000	-4140.000
10 Net Profit (loss) from discontinuing operations before tax	0.000	0.000	0.000	0.000	0.000	0.000
11 Tax Expense of discontinuing operations	0.000	0.000	0.000	0.000	0.000	0.000
12 Net Profit (loss) from discontinuing operations after tax	0.000	0.000	0.000	0.000	0.000	0.000
13 Net Profit (loss) for the Period	8763.000	1024.000	-202.000	9929.000	-4140.000	-4140.000
14 Details of equity share capital						
Paid-up equity share capital	50717.000	50717.000	50717.000	50717.000	50717.000	50717.000
15 Earnings per share						
Face value of equity share capital	10.000	10.000	10.000	10.000	10.000	10.000
i Basic earnings per share before extraordinary items	1.728	0.169	0.000	1.958	0.000	0.000
ii Diluted earnings per share before extraordinary items	1.728	0.169	0.000	1.958	0.000	0.000

Notes :

- The Above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 30th March 2018.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) PRESCRIBED UNDER SECTION 133 OF THE Companies Act, 2013, & other recognized accounting practices & policies to the extent applicable. Beginning from April 1st, 2017 company has for the first time adopted Ind AS with transition date of April 1st, 2017.
- The Income from Operations is from one segment namely "Pharmaceutical Industry".
- Previous period exp. have been regrouped / rearranged, wherever necessary.
- Taxes and depreciation are calculated on proportionate basis on annual estimated basis.
- The Ind AS compliant financial results, Pertaining to period ended Sep 30, 2016 have not been subject to limited review or audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- Reconciliation of Profit reported in accordance with previous Indian GAAP (IGAAP) to total comprehensive Income in accordance with Ind AS is given below:
31st march 2017 are changed due to application of Ind AS.
- The results for

Particulars

Particulars	Corresponding 3 months ended in the previous year march 31, 2017 (Rs in 000)
Profit for the period as per I GAAP	
Amortization of Goodwill	-202.000
Reclassification of net actuarial loss on defined obligation to other comprehensive income	0
Charge of group ESOP	0
Tax impact in Ind AS adjustment	0
Profit for the period as per Ind AS	0
Other comprehensive income as per Ind AS	-202.000
Total Comprehensive Income as per Ind AS	0

For and behalf of the Board

Place : Indore
Date : 30.5.2018

Sanjay Sethi
Managing Director

BERYL DRUGS LTD.
STATEMNET OF ASSETS & LIABILITIES

(Rs. In 000)

PARTICULARS	AS AT YEAR ENDED 31.3.2018 (AUDITED)	AS AT YEAR ENDED 31.3.2017 (AUDITED)
Equity & Liabilities		
1. Shareholder's fund		
Share Capital	50937.00	50937.00
Reserve & Surplus	17251.00	9840.00
Total (A)	68188.00	60777.00
2. Non Current Liabilities		
Other Long Term Borrowings	732.00	947.00
Long Term Provisions	1875.00	2135.00
Total (B)	2607.00	3082.00
3. Current Liabilities		
Short term Borrowing	13865.00	15954.00
Trade Payable	14149.00	12072.00
Other Current Liabilities	12003.00	14083.00
Short term Provisions	44.00	837.00
Total (C)	40061.00	42946.00
Total (A+B+C)	110856.00	106805.00
ASSETS		
1. Non Current Assets		
Fixed Assets	22126.00	22449.00
Intangible assets	62.00	62.00
Capital WIP	757.00	0.00
Deffered Tax Assets	3443.00	3186.00
Long term loans & advances	6514.00	6838.00
Non Current Investment	2171.00	4925.00
Total (D)	35073.00	37460.00
2. Current Assets		
Inventories	12539.00	26899.00
Trade Receivable	47809.00	30647.00
Cash & Cash Equivalent	3101.00	7653.00
Short Term Loans & Advances	0.00	1107.00
Other Current Assets	12334.00	3039.00
Total (E)	75783.00	69345.00
Total (D+E)	110856.00	106805.00

Note : *Previous period figures have been regrouped / rearranged, wherever necessary.

*The results for 31st march 2017 are changed due to application of Ind AS.

For BERYL DRUGS LTD.,

[Signature]
Managing Director/Director



CA. PRATEEK JAIN
B.COM, FCA

PRATEEK JAIN & Co.

CHARTERED ACCOUNTANTS

FRN- 009494C

212, Shalimar Corporate Centre,
8-B, South Tukoganj, Indore-452001 (M.P.)
☎ 0731 2520955 📠 +91 98270 13187
Email : caprateekjain@gmail.com

INDEPENDENT AUDITORS REPORT

**To Board of Directors of
M/s Beryl Drugs Limited
Indore (M.P.)**

We have audited the Statements of Financial Results of **M/s Beryl Drugs Limited** (the Company) for the year ended March, 31 2018 ('the Statement').

Being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. This Statements, which is the responsibility of the Company's Managements and approved by the Board of Directors, has been prepared on the basis of the related financial statements which are in accordance with the Accounting Standards prescribed under section 133 of the Companies Act, 2013, as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion of the statements.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements (s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



13 MAY 2018

In our opinion to the best of our information and according to the explanations given the statements:

- (I) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard;
- (II) Give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2018 as well as the year to date results for the period from April 1, 2017 to March 31, 2018.

Date: 30.05.2018
Place : Indore

For Prateek Jain & Co.
Chartered Accounts
FRN : 009494C



(CA Prateek Jain)
M.No. 079214



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.) INDIA.

Tel. : (0731) 2517677 E-mail : beryldrugs25@yahoo.com CIN : L02423MP1993PLC007840

DECLARATION

Pursuant to the Regulation 33(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015, and amendments made therein vide SEBI Circular No SEBI/LAD-NRO/GN/2016-17 dated 25th May, 2016 and further amendment dated 27th May, 2016, We, the undersigned do hereby declare that in the Audit Report, accompanying the Annual Audited Financial Statements of M/s Beryl Drugs Limited for the financial year ended on 31.03.2018, the Auditor does not expressed any Modified Opinion(s)/ Audit Qualification(s)/ or other Reservation(s) and accordingly the the statement on impact of audit qualifications is not required to be given.

<p>For Prateek Jain & Company</p> <p>FR. No. 009494C</p> <p></p> <p>Prateek Jain</p> <p>Membership No. : 79214</p> <p></p>	<p>For Beryl Drugs Limited</p> <p></p> <p>Mr. Sanjay Sethi Managing Director DIN: 00090277</p>
<p>For Beryl Drugs Limited</p> <p></p> <p>Mr. Ashish Baraskar Chief Financial Officer</p>	<p>For Beryl Drugs Limited</p> <p></p> <p>Mr. Yashesh Vashistha Chairman of Audit Committee</p>